Tocilizumab reduces mortality risk in severe COVID-19 patients
Objectives:
People who are exposed to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) could develop a potentially fatal disease with lung involvement and severe cytokine storm syndrome (CSS) - coronavirus disease 2019 (COVID-19). Tocilizumab (TCZ) was administered to these subjects, despite the lack of randomized clinical trial data. Hence, summarizing data on the mortality rate and related risks factors may help physicians to correctly administer tocilizumab. Therefore, this review article has been conducted.